Results from the final-stage trial administered by GSK appeared to demonstrate that the vaccine only provided “modest protection” for babies aged six to 12 weeks, with a reduction in the contraction of the disease by only 30%, a much lower number than what had been touted by those promoting the jab in the industry and the corporate media.
Reuters also reports that for children after the age of six months, a 65% rate was established. For children of five to 17 months old, the researchers claim a protection of around 50%.
In response to what Reuters has dubbed a “surprisingly poor result” for the vaccine, Bill Gates stated, “The efficacy came back lower than we had hoped, but developing a vaccine against a parasite is a very hard thing to do.”
Indeed, Gates is correct in suggesting the difficulty for creating a vaccine for a Protozoan, the type of parasite which causes malaria, This is because vaccines are supposedly designed to protect against viruses. Thus, the Mosquirix vaccine enters into the growing science of DNA vaccines – a research field which is expanding but also one in which the science is still very much out in regards to effectiveness, safety, and even possibility.
Nevertheless, GSK has announced that it will not be giving up in the attempt to develop Mosquirix into a more “effective” vaccine, and will be working with governments and international groups in order to fund the operation. GSK claims it does not plan to make a profit from Mosquirix, although it admits that it will be charging a 5% profit margin on the product. The funding for the development and rollout, of course, will be coming from the governments and international groups mentioned above, meaning it is the cash-strapped taxpayer who must shovel out the cash for yet another eugenics program aimed at poor Africans.
Interestingly enough, it was Bill Gates himself who once stated, “The world today has 6.8 billion people… that’s headed up to about 9 billion. Now if we do a really great job on new vaccines, health care, reproductive health services, we could lower that by perhaps 10 or 15 percent.”
Of course, it bears noting, especially in this context, that the results of the GSK study show only a 30% efficacy rate yet the companies, governments, and international “groups” behind the push are continuing to move forward with plans for yet more vaccination programs whose harmful effects have not been properly studied.
Yet, even the 30% itself is highly suspect considering the fact that there has never been a study proving that vaccines are either safe or effective that itself was not connected to a vaccine maker or pharmaceutical company.
The fact that the ineffectiveness of the malaria vaccine is being announced openly by the corporation that created it as well as one of the most notorious vaccine pushers in the world is striking. With this in mind, one could be led to suppose that the real percentage of efficacy might be even lower if non-politicized science were applied to it.
In the end, the real goal of such vaccine programs as those currently being funded in Africa is a eugenics-based, population reduction philosophy that permeates governments, corporations, NGO’s, and academia. Unfortunately, it is for this reason that open the open failure of the malaria vaccine will do little to deter the expense of more money, more time, and more propaganda being spent toward the goal of vaccinating and reducing the vast majority of the population of Africa.
Read other articles by Brandon Turbeville here.
Brandon Turbeville is an author out of Florence, South Carolina. He has a Bachelor’s Degree from Francis Marion University and is the author of three books, Codex Alimentarius — The End of Health Freedom, 7 Real Conspiracies, and Five Sense Solutions and Dispatches From a Dissident. Turbeville has published over 175 articles dealing on a wide variety of subjects including health, economics, government corruption, and civil liberties. Brandon Turbeville’s podcast Truth on The Tracks can be found every Monday night 9 pm EST at UCYTV. He is available for radio and TV interviews. Please contact activistpost (at) gmail.com.